TY - JOUR
T1 - Adoptive cell therapy for acute myeloid leukemia
AU - Ma, Hongbing
AU - Iyer, Swaminathan Padmanabhan
AU - Parmar, Simrit
AU - Gong, Yuping
N1 - Funding Information:
The first author was supported by the China Scholarship Council for 1 year’s study at MD Anderson Cancer Center.
Publisher Copyright:
© 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019
Y1 - 2019
N2 - Acute myeloid leukemia (AML) is the most common tumor in adult patients, most of the patients have a poor prognosis even after high-intensity chemotherapy, especially for relapsed, refractory or elderly patients. Therefore, new methods are needed to change the outcomes. In recent years, an increasing number of immune-therapies are emerging where adoptive cell therapy, a special immunotherapy, has become a promising strategy for AML. Here, we review the clinical application and advancement of donor lymphocyte infusion, chimeric-antigen receptor (CAR) T cell therapy, natural killer (NK) cell therapy and dendritic cell vaccination for AML, hopefully providing an overview of clinical aspects of advances in adoptive cell therapy for AML.
AB - Acute myeloid leukemia (AML) is the most common tumor in adult patients, most of the patients have a poor prognosis even after high-intensity chemotherapy, especially for relapsed, refractory or elderly patients. Therefore, new methods are needed to change the outcomes. In recent years, an increasing number of immune-therapies are emerging where adoptive cell therapy, a special immunotherapy, has become a promising strategy for AML. Here, we review the clinical application and advancement of donor lymphocyte infusion, chimeric-antigen receptor (CAR) T cell therapy, natural killer (NK) cell therapy and dendritic cell vaccination for AML, hopefully providing an overview of clinical aspects of advances in adoptive cell therapy for AML.
KW - Acute myeloid leukemia
KW - Cell therapy
KW - Immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85067199974&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067199974&partnerID=8YFLogxK
U2 - 10.1080/10428194.2018.1553300
DO - 10.1080/10428194.2018.1553300
M3 - Review article
C2 - 30628504
AN - SCOPUS:85067199974
SN - 1042-8194
VL - 60
SP - 1370
EP - 1380
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 6
ER -